Drug Profile
Research programme: therapeutics - Merck/The Institute for Research in Immunology and Cancer
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Merck & Co; University of Montreal
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in Canada
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in USA
- 14 Feb 2014 Early research in Cancer in Canada (unspecified route)